Project Grant R01CA288612
Award Date
1/1/25
Completion Date
12/31/29
Dollars Obligated
$696K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Charlottesville, VA, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $227,906 to The Trustees of the University of Pennsylvania to conduct research on the immunomodulatory effects of the FDA-approved drug Photofrin and other heme oxygenase-1 (HO-1) inducing compounds in malignant pleural mesothelioma (MPM). The research aims to: 1) characterize the tumor control and antitumor immunity generated by Photofrin and other HO-1 inducers, and 2) utilize...
This federal Project Grant award, with an obligated amount of $3,705,142.00, was issued by the Defense Health Agency (DHA) under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant supports a Phase 2 study of sacituzumab govitecan-hziyin, a novel immunotherapy, in patients with previously treated mesotheliomas. The research is being conducted by the Sloan-Kettering Institute for Cancer Research, a prominent non-profit cancer research organization in New...
The U.S. National Cancer Institute has awarded a $1,003,173 Project Grant (CFDA 93.395 - Cancer Treatment Research) to Radiopharmaceutical Imaging and Dosimetry, LLC, a for-profit company based in Baltimore, Maryland. The grant is for the development of a prototype web/cloud-based quantitative SPECT reconstruction software system that can be used for clinical trials and dosimetry of radiopharmaceutical cancer therapies, particularly those utilizing alpha-emitting radionuclides. The key...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $676,567 to support preclinical research on a novel theranostic approach targeting transforming growth factor beta (TGFβ) for cancer treatment. The award supports a multi-year project led by the University of California, San Francisco to radiolabel a clinically validated TGFβ-neutralizing antibody with imaging (89Zr) and therapeutic (177Lu) isotopes. The goal is to evaluate...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding of $738,698 to the Beckman Research Institute of the City of Hope to conduct research on a novel targeted radiotherapy approach for the treatment of relapsed and refractory acute myelogenous leukemia (AML) in older patients. The key objectives are to establish the appropriate dosing of the anti-CD38 targeted alpha therapy (225Ac-DOTA-daratumumab) when combined with total...
The U.S. National Cancer Institute awarded a $581,723 Project Grant to The Johns Hopkins University to develop an advanced imaging system called the "Alpha-Scope" for in vivo 3D autoradiography of radiopharmaceuticals used in cancer treatment. The objective is to provide high-resolution, real-time mapping of the distribution and kinetics of radiopharmaceuticals labeled with beta-emitting or alpha-emitting radionuclides in small animal models. This new imaging capability will support...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $415,259 to the Rector & Visitors of the University of Virginia to conduct research on the role of long noncoding RNAs in acute myeloid leukemia (AML). The project aims to 1) determine the role of a specific regulatory RNA in primary and relapsed AML, and 2) define the mechanism underlying its deregulation in AML. This research will provide insights into how noncoding RNAs...
This $135,573 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) will support the following key objectives at the University of Virginia Comprehensive Cancer Center (UVA): Increase UVA's accrual depth and breadth in National Clinical Trials Network (NCTN) and Experimental Therapeutics Clinical Trials Network (ETCTN) clinical trials by identifying and overcoming provider and patient barriers. Increase UVA's leadership and collaboration in...
The National Cancer Institute (NCI) awarded a $898,497 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to Radiopharmaceutical Imaging and Dosimetry, LLC to develop a cloud-based, customer-responsive dosimetry tool for alpha-particle emitting radiopharmaceutical therapies. The key objectives are to: 1) establish a library of microscale S-values and apportionment factors for dose-limiting tissues, 2) implement a macro-to-micro dosimetry methodology to enable...
This federal Project Grant award of $644,622 from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) aims to enhance radioligand therapy for prostate cancer through the development of biomarker and dosimetry-guided personalized treatment approaches. The key objectives are to: 1) develop a novel method for bone marrow dosimetry using macro/micro Monte Carlo modeling, 2) build predictive models to estimate absorbed radiation doses from pre-therapy PET...